Compare Mesoblast Limited (MESO) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs SAP SE — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.21B), while SAP SE trades at $207.11 (market cap $240.81B). The key difference: SAP SE is far larger — about 109× Mesoblast Limited's market cap, and SAP SE pays a 1.4% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | SAP | |
|---|---|---|
Market Cap | $2.21B | $240.81B |
Sector | Technology | Technology |
52-Week High | $20.96 | $280.46 |
52-Week Low | $12.88 | $146.38 |
Enterprise Value | $2.21B | $239.52B |
Dividend Yield | — | 1.4% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
